Factors for Consideration when Choosing an Adjuvant Therapy Regimen for Patients with MIBC

Following positive phase 1 results in patients with previously treated advanced urothelial carcinoma, the FDA granted Fast Track Designation for the novel AHR inhibitor IK-175.

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.

Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.

Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.